Dose adjustments in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)

被引：0

作者：

Kreuter, M. ^{[1
,2
]}

Highland, K. B. ^{[3
]}

Kuwana, M. ^{[4
]}

Azuma, A. ^{[5
]}

Maher, T. ^{[6
,7
]}

Mayes, M. D. ^{[8
]}

Raghu, G. ^{[9
]}

Girard, M. ^{[10
]}

Kohlbrenner, V ^{[11
]}

Clerisme-Beaty, E. ^{[12
]}

Alves, M. ^{[12
]}

Distler, O. ^{[13
]}

机构：

[1] Heidelberg Univ, Thoraxklin, Ctr Interstitial & Rare Lung Dis Pneumol & Resp C, Heidelberg, Germany

[2] German Ctr Lung Res, Giessen, Germany

[3] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA

[4] Nippon Med Sch, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan

[5] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan

[6] Imperial Coll London, Natl Heart & Lung Inst, London, England

[7] Royal Brompton Hosp, Natl Inst Hlth Res, Clin Res Facil, London, England

[8] Univ Texas Mcgovern Med Sch, Div Rheumatol & Clin Immunogenet, Houston, TX USA

[9] Univ Washington, Seattle, WA 98195 USA

[10] Boehringer Ingelheim France SAS, Reims, France

[11] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA

[12] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[13] Univ Hosp Zurich, Dept Rheumatol, Zurich, Switzerland

来源：

PNEUMOLOGIE | 2020年 / 74卷

关键词：

D O I：

10.1055/s-0039-3403183

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

P151

引用

页码：S55 / S56

页数：2